

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

Granta-519

RRID:CVCL_1818

Type: Cell Line

Proper Citation

RRID:CVCL_1818

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1818

Proper Citation: RRID:CVCL_1818

Description: Cell line Granta-519 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Mantle cell lymphoma

Defining Citation: [PMID:7849311](#), [PMID:8036001](#), [PMID:9001420](#), [PMID:12169673](#), [PMID:12683869](#), [PMID:15350304](#), [PMID:16448697](#), [PMID:16960149](#), [PMID:17332242](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:21746927](#), [PMID:22460905](#), [PMID:24362935](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26194763](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Granta-519

Synonyms: GRANTA-519, Granta 519, Granta519, GRANTA519, G-519, G519

Cross References: CLO:CLO_0003561, EFO:EFO_0005369, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03472258,

BioSample:SAMN10988429, cancercellines:CVCL_1818, Cell_Model_Passport:SIDM01058, ChEMBL-Cells:ChEMBL4483170, ChEMBL-Targets:ChEMBL4483240, Cosmic:1037808, Cosmic:1047113, Cosmic:1291032, Cosmic:1881780, Cosmic:2296989, Cosmic:2756233, Cosmic-CLP:1303897, DepMap:ACH-000073, DSMZ:ACC-342, DSMZCellDive:ACC-342, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1303897, GEO:GSM95562, GEO:GSM95567, GEO:GSM104459, GEO:GSM115802, GEO:GSM155069, GEO:GSM155070, GEO:GSM155071, GEO:GSM274840, GEO:GSM629484, GEO:GSM629485, GEO:GSM827167, GEO:GSM887028, GEO:GSM888098, GEO:GSM907517, GEO:GSM1266777, GEO:GSM1266778, GEO:GSM1374484, GEO:GSM1669815, GEO:GSM2322618, GEO:GSM3150245, IARC_TP53:25016, LiGeA:CCLE_863, LINCS_LDP:LCL-1126, Lonza:257, PharmacDB:GRANTA519_414_2019, PRIDE:PXD012087, PRIDE:PXD020750, PRIDE:PXD030304, Progenetix:CVCL_1818, PubChem_Cell_line:CVCL_1818, Wikidata:Q54871671

ID: CVCL_1818

Record Creation Time: 20220427T220218+0000

Record Last Update: 20260829T233413+0000

Ratings and Alerts

No rating or validation information has been found for Granta-519.

No alerts have been found for Granta-519.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Rosen EY, et al. (2026) Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1411.

Dell'Aversana C, et al. (2026) UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. Journal of hematology & oncology, 19(1).

Probst P, et al. (2025) Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. Molecular cancer therapeutics, 24(6), 803.

Liu P, et al. (2024) Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma. American journal of cancer research, 14(6), 2921.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Demajo S, et al. (2021) A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(1), 213.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. International journal of cancer, 148(1), 150.